TABLE 1.
Baseline characteristics
| Author, year | Study design | Age | No. of patients | Sex N (%) | Prognosis | Comorbidities N (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Males | Females | Discharged | Continued hospitalisation | Transferred to another hospital | Death | ||||||
| Middeldorp, 2020 | Cohort | 61 (14) | 198 | 130 (66) | 68 (34) | 136 (69) | 16 (8) | 8 (4) | 38 (19) | Active cancer | 7 (3.5) |
| Grillet, 2020 | Retrospective | 66 (13) | 100 | 70 | 30 | NA | NA | NA | NA | Cardiovascular Disease | 39 |
| Chronic Respiratory Insufficiency | 15 | ||||||||||
| T2DM | 20 | ||||||||||
| Malignancy | 20 | ||||||||||
| Zhang, 2020 | Retrospective | 63 (14) | 143 | 74 (51.71) | 69 (48.25) | 92 (64.3) | 19 (13.3) | NA | 32 (22.4) | HTN | 56 (39.2) |
| DM | 26 (18.2) | ||||||||||
| CAD | 17 (11.9) | ||||||||||
| Malignancy | 7 (4.9) | ||||||||||
| Cerebal Infarction | 5 (3.5) | ||||||||||
| Chronic Liver Disease | 5 (3.5) | ||||||||||
| CKD | 4 (2.8) | ||||||||||
| Lorant, 2020 | Retrospective | 64 (22) | 106 | 70 (66) | 36 (34) | NA | NA | NA | NA | NA | |
| Demelo, 2020 | Cohort | 68.1 (14.5) | 156 | 102 (66) | 54 (34) | NA | NA | NA | NA | Active Cancer | 16 (10.3) |
| Lodigiani, 2020 | Cohort | 66 | 388 | 264 (68) | 124 (32) | NA | NA | NA | NA | HTN | 183 (47.2) |
| DM | 88 (22.7) | ||||||||||
| Dyslipidemia | 76 (19.6) | ||||||||||
| Chronic Renal Dysfunction | 61 (15.7) | ||||||||||
| Active Cancer | 25 (6.4) | ||||||||||
| Poyiadi, 2020 | Retrospective | 62 (16) | 328 | 148 (45) | 180 (55) | NA | NA | NA | NA | Cancer History | 14 |
| DM | 38 | ||||||||||
| HTN | 61 | ||||||||||
| COPD | 13 | ||||||||||
| CHF | 9 | ||||||||||
| Cui, 2020 | Retrospective | 59.9 | 81 | 37 (46) | 44 (54) | 9 (11) | 64 (79) | 8 (10) | HTN | 20 (25) | |
| DM | 8 (10) | ||||||||||
| CHD | 10 (12) | ||||||||||
| Coronary Heart Disease | 10 (12) | ||||||||||
| Bilalogu et al, 2020 | Retrospective Study | 64 | 3334 | 2014 (60.4) | 1320 (39.6) | NA | NA | NA | NA | Myocadial Infarction | 195 |
| Congestive Heart failure | 279 | ||||||||||
| HTN | 1676 | ||||||||||
| Diabetes | 1246 | ||||||||||
| Hyperlipidemia | 1285 | ||||||||||
| Coronary artery disease | 617 | ||||||||||
| Fauvel et al, 2020 | Cohort Study | 64 | 1240 | 721 (58.1) | 519 (41.9) | NA | NA | NA | 151 (12.2) | HTN | 559 (45.4) |
| Diabetes | 268 (21.7) | ||||||||||
| Dyslipidemia | 316 (25.6) | ||||||||||
| Cardiovascular disease | 19 (1.6) | ||||||||||
| COPD | 77 (6.2) | ||||||||||
| CKD | 126 (10.3) | ||||||||||
| Stroke | 94 (7.7) | ||||||||||
| Peripheral arterial disease | 60 (4.9) | ||||||||||
| Atrial fibrillation | 117 (9.5) | ||||||||||
| CHF | 117 (9.5) | ||||||||||
| CAD | 133 (10.7) | ||||||||||
| Malignancy | 167 (13.7) | ||||||||||
| Trimaille et al, 2020 | Cohort Study | 62.2 | 289 | 171 (59.2) | 118 (40.8) | 236 (88.7) | NA | NA | 24 (8.3) | NA | NA |
| Whyte et al, 2020 | Cohort Study | 63.5 | 214 | 129 | 85 | NA | 36 | NA | 31 | Malignancy | 16 |
| Haemoptysis | 12 | ||||||||||
| Artifoni et al, 2020 | Cohort Study | 64 | 71 | 43 (60.6) | 28 (39.4) | NA | NA | NA | NA | HTN | 32 (60) |
| Diabetes | 14 (20) | ||||||||||
| Cancer | 4 (6) | ||||||||||
Data are presented as median (IQR) or number (%).
Abbreviations: CAD, coronary artery disease; CHD, coronary heart disease; CKD, chronic kidney disease; CHF, coronary heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; IQR, interquartile range; NA, not available; No., number; T2DM, diabetes mellitus type 2.